Calvary Mater Newcastle

Waratah 2298

3 studies enrolling now · 12 studies all time

What they study most

Advanced Solid Tumor, Advanced Solid Tumor, Adult, Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC), Anaplastic Large-Cell Lymphoma, Carcinoma, Transitional Cell, Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS), Malignant Pleural Mesothelioma, Melanoma, Metastatic Castrate Resistant Prostate Cancer, Myelodysplastic Syndromes (MDS)

Studies at this site

• Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation — Recruiting now
• A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract — Recruiting now
• A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma — Recruiting now
• A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer — Running, not enrolling
• Mirdametinib + BGB-3245 in Advanced Solid Tumors — Stopped early
• A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) — Running, not enrolling
• Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004) — Running, not enrolling
• Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma — Running, not enrolling
• MGC018 With or Without MGA012 in Advanced Solid Tumors — Stopped early
• Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer — Completed
• ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas — Completed
• Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma — Stopped early